Briefing Industry news Industry briefing NEWS FDA grants priority review for Biogen’s tofersen to treat ALS The US FDA has granted priority review for Biogen’s New Drug Application (NDA) for its gene therapy tofersen to treat superoxide dismutase 1 (SOD1) amyotrophic lateral sclerosis (ALS) news Amgen to acquire biopharma firm ChemoCentryx for $3.7bn Amgen has signed a definitive agreement to acquire ChemoCentryx for $52 for each share in cash or a total enterprise cost of nearly $3.7bn Briefing BeiGene reports Phase III tislelizumab data in hepatocellular cancer BeiGene reported positive data from the Phase III RATIONALE 301 trial of tislelizumab as a first-line therapy for adult unresectable HCC patients Industry news Industry briefing 08/19/2022 18:28:48
Briefing
BeiGene reports Phase III tislelizumab data in hepatocellular cancer
BeiGene reported positive data from the Phase III RATIONALE 301 trial of tislelizumab as a first-line therapy for adult unresectable HCC patients